Considerations with the use of biological therapy in the treatment of rheumatoid arthritis.
about
Promiscuous drugs compared to selective drugs (promiscuity can be a virtue)Recent developments in targeting access to high cost medicines in Australia.Immunomodulation in recurrent miscarriageIdentification of an in vivo orally active dual-binding protein-protein interaction inhibitor targeting TNFα through combined in silico/in vitro/in vivo screeningRationale of using different biological therapies in rheumatoid arthritis.Bone erosions in rheumatoid arthritis can be repaired through reduction in disease activity with conventional disease-modifying antirheumatic drugsLong term safety of etanercept in elderly subjects with rheumatic diseases.Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.Leflunomide: long-term clinical experience and new uses.Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007Tacrolimus in rheumatoid arthritis.Etanercept: an introduction.The impact of biologic response modifiers on hepatitis B virus infection.Multiple squamous cell carcinomas in the setting of psoriasis treated with etanercept: a report of four cases and review of the literature.The age-risk relationship of hematologic malignancies in patients with rheumatoid arthritis: a nationwide retrospective cohort study.Natural History of Crohn's Disease in Elderly Patients Diagnosed Over the Age of 70 Years: A Population-Based Study.The different expression patterns of interleukin-1 receptor antagonist in systemic lupus erythematosus.
P2860
Q24799034-026724E7-B89C-473C-B807-E51C51AD4C90Q25254962-1F9E11BB-AC3A-481A-B040-21FB3A394747Q26995890-46D1A009-C97A-4EE4-8CC0-E476DDE9A3F9Q30855659-E1635761-46CC-494B-9CF1-BAEBE2FB8E2AQ34153073-68B47B37-2128-4045-8129-5F07B87ADACDQ34897514-A338F873-0E1F-4908-A898-982A23DF039AQ35636875-F2A337D5-72EA-4481-BFBE-11503E93BD99Q35638252-0A100493-25B4-4BBA-952F-3CE212F94D64Q36150789-E92034E5-B6C6-4442-92AB-294C15D1FB81Q36171750-4133E848-171F-4397-89FE-DB9DBB2A4E06Q36349618-EC38F86C-1DC5-413B-990F-E9B6443E2394Q37754607-A80FBBE5-9EDF-41C8-9EE6-18106936A543Q37832503-F72F2ED0-7B5F-43A0-8DBB-CA430939B73CQ37957993-98F4F651-96B5-43D6-B21B-064EB82C7F37Q41728502-6AC62AFD-C9D1-4A82-B9A6-C8E69664D838Q53097570-4BB793C5-5C5F-41E6-AA28-17BF199E2042Q54566648-2FDC051F-BAAB-4EE1-832F-B5A52BC0D40B
P2860
Considerations with the use of biological therapy in the treatment of rheumatoid arthritis.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Considerations with the use of ...... tment of rheumatoid arthritis.
@ast
Considerations with the use of ...... tment of rheumatoid arthritis.
@en
type
label
Considerations with the use of ...... tment of rheumatoid arthritis.
@ast
Considerations with the use of ...... tment of rheumatoid arthritis.
@en
prefLabel
Considerations with the use of ...... tment of rheumatoid arthritis.
@ast
Considerations with the use of ...... tment of rheumatoid arthritis.
@en
P2093
P2860
P356
P1476
Considerations with the use of ...... tment of rheumatoid arthritis.
@en
P2093
Imran Iqbal
Richard L Stern
Roy M Fleischmann
P2860
P304
P356
10.1517/14740338.3.5.391
P407
P577
2004-09-01T00:00:00Z